Martin Brenner

Accomplished, enthusiastic, and results-oriented biotechnology executive with extensive experience leading scientific innovation and corporate transformation. Proven track record as Chief Executive Officer and Chief Scientific Officer, successfully transforming iBio from a legacy CDMO into an AI-enabled biotechnology company focused on discovering and developing differentiated antibody therapeutics for obesity and cardiometabolic disease. Strong leadership record in building and leading high-performing research and cross-functional drug development teams. Demonstrated success in defining corporate strategy, rebuilding research organizations, integrating AI into drug discovery, establishing strategic partnerships, and advancing innovative therapeutics from discovery through clinical development-including leading the first molecule discovered from the iBio platform from concept to first-in-human dosing in approximately two years.